AKT1 and melanoma: A preclinical study investigating cabozantinib treatment of cell lines derived from melanoma brain metastases demonstrated the ability of the inhibitor to significantly reduce viability of cells in monolayer and 3D spheroid cultures, reduce migration and colony formation, and downregulate phosphorylation of Akt and MEK1/2 (Mannsåker et al., 2021).